Evolent Health (NYSE:EVH) Price Target Lowered to $19.00 at Barclays

Evolent Health (NYSE:EVH) had its price objective reduced by Barclays from $39.00 to $19.00 in a report released on Monday morning,Benzinga reports. They currently have an overweight rating on the technology company’s stock.

A number of other analysts have also recently commented on the stock. Truist Financial restated a “buy” rating and set a $33.00 price target on shares of Evolent Health in a research note on Tuesday, August 27th. JPMorgan Chase & Co. raised their price target on Evolent Health from $36.00 to $45.00 and gave the stock an “overweight” rating in a report on Monday, August 19th. KeyCorp began coverage on Evolent Health in a research note on Friday, October 11th. They set an “overweight” rating and a $35.00 price objective on the stock. Citigroup cut their target price on Evolent Health from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. Finally, Stephens lowered Evolent Health from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $38.00 to $16.00 in a report on Friday, November 8th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $29.50.

Evolent Health Stock Performance

Shares of NYSE EVH opened at $12.67 on Monday. The business’s fifty day moving average price is $25.47 and its 200-day moving average price is $24.45. Evolent Health has a one year low of $12.31 and a one year high of $35.00. The company has a quick ratio of 1.08, a current ratio of 1.04 and a debt-to-equity ratio of 0.58.

Insider Transactions at Evolent Health

In related news, COO Emily Ann Rafferty sold 8,861 shares of Evolent Health stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total transaction of $265,830.00. Following the completion of the transaction, the chief operating officer now directly owns 63,408 shares of the company’s stock, valued at $1,902,240. This trade represents a 12.26 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, President Daniel Joseph Mccarthy sold 23,693 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $30.89, for a total value of $731,876.77. Following the completion of the sale, the president now directly owns 198,809 shares in the company, valued at approximately $6,141,210.01. This represents a 10.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 307,291 shares of company stock valued at $9,290,385. Company insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On Evolent Health

A number of large investors have recently added to or reduced their stakes in EVH. Headlands Technologies LLC bought a new stake in shares of Evolent Health during the 1st quarter valued at about $46,000. Covestor Ltd increased its holdings in Evolent Health by 138.1% during the third quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock valued at $40,000 after buying an additional 826 shares during the last quarter. GAMMA Investing LLC raised its position in Evolent Health by 5,365.5% in the third quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock worth $45,000 after acquiring an additional 1,556 shares during the period. Quarry LP bought a new position in Evolent Health in the second quarter worth approximately $32,000. Finally, Canada Pension Plan Investment Board purchased a new position in shares of Evolent Health during the 2nd quarter worth $61,000.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.